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Introduction
Intravenous iron supplementation is widely used to treat iron deficiency and iron deficiency anaemia when oral iron administration is ineffective or poorly tolerated [1] [2] [3] . Intravenous iron is also administered in combination with erythropoiesis-stimulating agents to treat iron deficiency in chronic kidney disease and chemotherapy-induced anaemia. Acute reactions to intravenous iron infusions are rare, but when they occur, they can be life-threatening. The possibility of hypersensitivity reactions (including anaphylaxis) to highmolecular-weight iron dextran has traditionally limited the indications for the intravenous administration of iron. Newly approved iron formulations, like ferric carboxymaltose (Ferinject ® ) and iron isomaltoside-1000 (Monofer ® ), have the advantage of a lower risk for infusion reactions and can be given in a higher dose due to their lower molecular weight [4] . However, acute reactions have also been reported for these newly approved iron formulations [5] .
In a large teaching hospital in Rotterdam, the Netherlands, both ferric carboxymaltose (up to and including 2012) and iron isomaltoside-1000 (since 2013) have been used to treat patients with iron deficiency and iron deficiency anaemia as the first drug of choice. In February 2013 ferric carboxymaltose was replaced by iron isomaltoside-1000 due to significantly lower drug costs. After the introduction of iron isomaltoside-1000, physicians expressed their concerns about the safety, reporting infusion reactions, dyspnoea, palpitations, nausea and headache. An evaluation revealed six hypersensitivity reactions (HSRs) in 66 administrations of iron isomaltoside-1000 (9.1%). This percentage corresponds with information on HSRs available from the summary of product characteristics (SPC) of isomaltoside-1000 and ferric carboxymaltose [6, 7] . Following these experiences with regard to HSRs to iron isomaltoside-1000 in 2013, our hospital switched back to ferric carboxymaltose in January 2014.
In November 2013 the European Medicines Agency (EMA) published an assessment report based on concerns regarding hypersensitivity reactions of products containing intravenous iron. The EMA's Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of these medicines are greater than their risks, provided that adequate measures are taken to minimize the risk of allergic reactions. As a result, the EMA published strict recommendations for the use of intravenous iron:
• All prescribers should inform patients of the risk and seriousness of a hypersensitivity reaction and the importance of seeking medical attention if a reaction occurs.
• The risk of hypersensitivity is increased in patients with known allergies or immune or inflammatory conditions and in patients with a history of severe asthma, eczema or other atopic allergy [8] .
A PubMed search using the terms 'ferric carboxymaltose', 'iron isomaltoside-1000' and 'hypersensitivity' as subject headings or mentioned in the title or abstract showed that comparative studies of HSRs of the newer intravenous iron formulations, specifically ferric carboxymaltose and iron isomaltoside-1000, are very limited [9] . Bager et al. [9] found a higher risk of mild HSRs with iron isomaltoside-1000 administration when compared to ferric carboxymaltose administration. However, only patients from the Department of Hepatology and Gastroenterology were included in this study, and factors associated with the occurrence of HSRs were not investigated.
Based on the assumption of more HSRs with iron isomaltoside-1000 administrations and the lack of evidence, we initiated a comparative study of hypersensitivity reactions of iron isomaltoside-1000 and ferric carboxymaltoside. The aim of the study was to compare the risk for HSRs with the intravenous administration of iron isomaltoside-1000 and ferric carboxymaltose for the treatment of iron deficiency and iron deficiency anaemia in daily clinical practice. Also, factors associated with the occurrence of HSRs were investigated.
Methods

Design and patients
Our study was a single centre cohort study conducted at the Franciscus Gasthuis & Vlietland, Rotterdam, the Netherlands. Intravenous administration of iron isomaltoside-1000 was given between 1 February 2013 and 31 December 2013 and ferric carboxymaltose between 1 January 2014 and 31 December 2014 for the treatment of iron deficiency and iron deficiency anaemia.
Included were all patients with one or more administrations of iron isomaltoside-1000 or ferric carboxymaltose between February 2013 and December 2014. Patients on dialysis were excluded, because the first drug of choice for these patients in this period was iron sucrose (Venofer ® ) in our hospital. Furthermore, patients with known allergies to intravenous iron were excluded. The study was approved by our institutional review board and did not fall under the Medical Research Involving Human Subjects Act (WMO).
Interventions
Iron isomaltoside-1000 and ferric carboxymaltose were used at a dosage of 1000 mg. Iron isomaltoside-1000 was administered in 60 min and ferric carboxymaltose was administered in 15 min, according to manufacturer's instructions [6, 7] .
Data collection
An HSR registration form was developed to record (suspected) HSRs prospectively. The form was based on a checklist 'Adverse Events' provided by the pharmaceutical company of iron isomaltoside-1000. Nurses and physicians were instructed to fill out the HSR registration form for every administration of ferric carboxymaltose or iron isomaltoside-1000 in the study period. The HSR registration form was used to register patient information, name of the iron formulation used, date of administration and indication. In case of a (suspected) HSR, the nurse or the physician had to complete the form with the description of the reaction, time to the reaction (in minutes) since administration, clinical information (e.g. blood pressure, heart rate), clinical course after the onset of the reaction and the history of previous intravenous iron administrations.
Later, it appeared that not all HSR registration forms were filled out for every administration of intravenous iron in the study period. To avoid the risk of selection bias, we retrospectively identified all intravenous iron administrations in the study period through the hospital's electronic medical registry (ChipSoft) and added the missing data to the prospectively collected data. The following information was collected from the patients' electronic medical records: sex, age, department, diagnosis, dose, type of intravenous iron given, administration date, presence of comorbidities, history of intravenous iron and any data on HSRs and complications. Intravenous iron administrations accidently registered twice on the same date in the hospital's electronic medical registry were excluded.
Causal relationship and hypersensitivity reaction classification
Causal relationship between the administration of intravenous iron and HSRs was determined for every reaction using the Naranjo score [10] .
HSRs were distinguished into serious and non-serious HSRs using the Ring and Messmer classification (see Table 1 ) [11] . To reduce interrater variability, all HSRs were independently categorized by a panel of two pharmacists (M.B.M. and H.L.v.d.H.) and one physician (A.J.P.v.T.). Next, their grades were compared and when dissensus existed, the panel members reviewed their own classifications and discussed until consensus was reached about the grade. All HSRs were also reported to the Netherlands Pharmacovigilance Centre Lareb.
Statistical methods
No formal sample size calculation was performed. We included all patients in the analyses that received at least one intravenous iron administration during the study period.
Variables were described with descriptive statistics: n (%) for nominal and ordinal variables and mean (95% confidence interval, CI) or median (inter-quartile range, IQR) for the continuous variables, depending on the shape of the distribution. 
Results
Patients and intravenous iron administrations
During the study period, intravenous iron was administered 1332 times. Of these, 496/1332 (37.2%) administrations were iron isomaltoside-1000 and 836/1332 (62.8%) ferric carboxymaltose. The HSR registration form was filled in prospectively for 327 of 496 (65.9%) administrations of iron isomaltoside-1000 and 304 of 836 (36.4%) administrations of ferric carboxymaltose. Table 2 presents patients' baseline characteristics. Approximately 70% of intravenous iron administrations were given to females, iron isomaltoside-1000 was more frequently used in the Department of Gastroenterology and ferric carboxymaltose was more frequently used in the Department of Gynaecology. In the iron isomaltoside-1000 group, 154/496 (31%) of the patients with an iron infusion had a comorbidity vs. 170/836 (20.3%) in the ferric carboxymaltose group. Patients with a gastrointestinal comorbidity received iron isomaltoside-1000 more frequently. Table 3 presents an overview of the HSRs for each intravenous iron formulation. The relative risk for HSRs was significantly lower for ferric carboxymaltose treatment (RR = 0.248, 95% CI: 0.145-0.426, P < 0.0001).
Hypersensitivity reactions
The most common HSRs were Ring & Messmer classification grades I and II. Three patients in the iron isomaltoside-1000 group experienced a grade III reaction, no grade IV reactions occurred and most of the patients in the iron isomaltoside-1000 group experienced HSRs within 30 min after the start of the infusion (see Table 3 ). The relative risk on grade I complications was not significantly higher in the iron isomaltoside-1000 group (RR = 0.647, 95% CI: 0.289-1.456).
Table 3
Overview of the hypersensitivity reactions (HSRs) in patients treated with ferric carboxymaltose or iron isomaltoside-1000, overall, and by Ring and Messmer classification, time to occurrence and Naranjo score The results of grade II complications indicate a significantly reduced risk of grade II HSRs after ferric carboxymaltose administration (RR = 0.123, 95% CI: 0.051-0.294). In every patient the infusion was stopped after an HSR occurred and clemastine was administered. All patients recovered. In addition, in 20 patients the infusion of intravenous iron was successfully resumed at a lower infusion rate after the HSR occurred, seven patients switched directly after the HSR to a different intravenous iron formulation with success, and 13 patients received a different intravenous iron formulation successfully several months/years after the HSR. Lastly, seven patients with an HSR on iron isomaltoside-1000 had previously received an infusion with ferric carboxymaltose without any problems. One patient with an HSR on ferric carboxymaltose had previously received an infusion with iron isomaltoside-1000 without any problem. Two patients reported an HSR > 24 h after the infusion.
All HSRs are determined as probable by the Naranjo score.
HSRs by subgroup Table 4 presents an overview of the HSRs by subgroup for each intravenous iron formulation. More females experienced an HSR and the age of most females was between 30 and 50 years.
In the iron isomaltoside-1000 group, more comorbidities were registered, 22 of the 43 administrations with an HSR, while in the ferric carboxymaltose group comorbidities were registered for three of the 18 administrations with an HSR (RR = 0.081, 95% CI: 0.024-0.269). For the iron isomaltoside-1000 group, 9 out of 22 comorbidities appeared to be gastrointestinal comorbidities.
Factors associated with the occurrence of HSRs Table 5 presents an overview of the factors associated with the occurrence of HSRs. Overall, the presence of a comorbidity, iron isomaltoside-1000 administration and age increased the risk of an HSR significantly. The presence of a comorbidity raises the incidence of an HSR by a factor of 3.6 (OR = 3.577), usage of iron isomaltoside-1000 increases the risk of HSR manifestations by a factor of 3.4 (OR = 3.411), and the risk of the occurrence of an HSR is approximately 4% lower for every year older a patient is (OR = 0.956). Males are associated with a lower risk for the occurrence of an HSR of approximately 75% (OR = 0.245) compared to females.
More specifically, in patients from the departments of Internal Medicine, Gastroenterology and Other, a significant effect on HSR manifestations is seen with the presence of a comorbidity (OR = 2.775), with the usage of iron isomaltoside-1000 (OR = 3.785) and a younger age (OR = 0.953) ( Table 5 ). In patients from the Department of Gynaecology, presence of a comorbidity showed a significant effect on the occurrence of an HSR (OR = 10.072) ( Table 5) .
Discussion
This study is to our knowledge the largest cohort study comparing HSRs after iron isomaltoside-1000 and ferric carboxymaltose administrations. The risk for HSRs was almost 75% (RR = 0.248) and the risk for Ring & Messmer grade II HSRs was about 88% (RR = 0.123) lower after ferric carboxymaltose treatment. The presence of a comorbidity raises the likelihood of an HSR by a factor of 3.6. Also, usage of iron isomaltoside-1000 and younger age increased the risk of an HSR.
Our study is in line with the EMA assessment report regarding a higher risk for HSR due to comorbidities and the study performed by Bager et al., showing a higher risk of mild HSRs with iron isomaltoside-1000 administration when compared to ferric carboxymaltose administration [8, 9] . Patients in our cohort had a wide range of comorbidities and it is known that certain comorbidities can increase the risk of hypersensitivity reactions [8] . However, it remains unclear whether the risk of hypersensitivity reactions is due to the intravenous iron formulation itself or to the allergies, immune system, inflammatory diseases or other patient conditions. Hypersensitivity reactions caused by intravenous iron formulations are attributed by some experts to the effects of bioactive labile iron. All intravenous iron formulations currently approved by regulatory authorities consist of iron-carbohydrate structures. The formulations differ from each other by the size of the core, the identity and the density of the surrounding carbohydrate. These Table 4 Overview of the hypersensitivity reactions (HSRs) by subgroup IQR, inter-quartile range; n.a. = not applicable
Comparison of hypersensitivity reactions of Monofer® vs. Ferinject® differences determine the amount of labile iron that is released. Whether the amount of bioactive labile iron between iron isomaltoside-1000 and ferric carboxymaltose differs substantially, possibly resulting in clinically relevant differences in HSRs, is unknown [12, 13] . Moreover, the immunologic basis of allergic hypersensitivity to the newer iron agents still remains unknown [14] . The two main theories are immunological IgE-mediated responses and complement activation-related pseudo-allergy [15] [16] [17] . However, there are data that support the concept of IgE-mediated hypersensitivity only for intravenous iron dextran therapy and not for the newer carbohydrate formulations [18, 19] . Recently, two systematic reviews and meta-analysis of randomized clinical trials comparing intravenous iron to another comparator showed that all currently available intravenous iron preparations appear to be safe [20, 21] . However, the study by Rognoni et al. [21] did not include trials with iron isomaltoside-1000 and the study by Avni et al. [20] included just one trial with iron isomaltoside-1000. Furthermore, the reviews included randomized clinical trials comparing intravenous iron with oral iron, placebo, intramuscular iron or no iron. No trials directly comparing ferric carboxymaltose with iron isomaltoside-1000 were included because they were not published at that time [20, 21] .
In our study, patients treated with iron isomaltoside-1000 had more comorbidities compared to patients treated with ferric carboxymaltose (31% vs. 20%). Most comorbidities were gastrointestinal. This is probably due to the fact that intravenous iron was mainly used in the Departments of Gastroenterology and Internal Medicine in our hospital. Interestingly, approximately 90% more HSRs were reported after administrations of iron isomaltoside-1000 in patients with a comorbidity (RR = 0.081). Moreover, irrespective of the intravenous iron formulation used, the presence of a comorbidity increased the occurrence rate of an HSR significantly by at least a factor of 2.8.
Another factor that seems to have an influence on the occurrence of HSRs is age. In the Department of Gynaecology, age did not have a significant influence. This is probably due to the fact that almost all patients treated in the Department of Gynaecology were between 30 and 50 years of age. However, for all patients, and specifically patients from the Departments of Internal Medicine, Gastroenterology and other, younger patients were at significantly higher risk of developing an HSR.
Finally, regarding sex, we observed a 75% reduced risk in the occurrence of HSRs in male patients after the administration of intravenous iron (OR = 0.245). However, in this study mainly females were included, which possibly underestimates the risk of the occurrence of HSRs in male patients. Nevertheless, also in the study by Bager et al. mainly females were included [9] .
The strengths of our study are the real-life clinical setting, the long period (approximately 2 years) over which all intravenous iron administrations were evaluated, and the fact that the HSRs were independently categorized. Another strength is the fact that we also investigated factors associated with the occurrence of HSRs. These factors can guide physicians in their choice for the administration of intravenous iron in specific patients in clinical practice. Table 5 Overview of factors associated with the occurrence of hypersensitivity reactions (HSRs)
Our study has some limitations. During the study period, more ferric carboxymaltose administrations have been registered in comparison to iron isomaltoside-1000. This might be explained by the fact that in recent years intravenous iron is more commonly prescribed in our hospital. We noticed a rise of 25% in prescriptions for intravenous iron from 2012 up to and including 2014. Furthermore, patients included in this study seem to differ with regard to the department where the intravenous iron was administered. Most importantly, information bias might be present: the fact that nurses and physicians in our hospital already had experience with ferric carboxymaltose before we switched to iron isomaltoside-1000 might have caused higher awareness of HSRs after isomaltoside-1000 administrations. Additionally, our HSR registration started after the first reactions of iron isomaltoside-1000 were reported to the hospital pharmacy. Also, the EMA assessment report published 10 months after the introduction of our HSR registration study could have caused higher awareness of HSRs among the nurses and physicians in our hospital. On the other hand, we noticed a decrease in the number of filled out HSR registration forms during the study period, which points towards a reduced awareness among the nurses and physicians.
Conclusions
Ferric carboxymaltose is associated with a 75% lower risk for HSRs compared with iron isomaltoside-1000 in our population. The presence of a comorbidity, as independent riskmodifying factor, raises the likelihood of an HSR by a factor of three regardless of the type of intravenous iron infusion. Further research is needed to clarify the underlying mechanism in different patient groups.
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